JP6427502B2 - アリールスルファターゼａの精製方法 - Google Patents

アリールスルファターゼａの精製方法 Download PDF

Info

Publication number
JP6427502B2
JP6427502B2 JP2015551870A JP2015551870A JP6427502B2 JP 6427502 B2 JP6427502 B2 JP 6427502B2 JP 2015551870 A JP2015551870 A JP 2015551870A JP 2015551870 A JP2015551870 A JP 2015551870A JP 6427502 B2 JP6427502 B2 JP 6427502B2
Authority
JP
Japan
Prior art keywords
chromatography
protein
asa
column
ultrafiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015551870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504040A (ja
JP2016504040A5 (enExample
Inventor
デーブ ニコルズ，
デーブ ニコルズ，
イゴール キノネス−ガルシア，
イゴール キノネス−ガルシア，
ビー リン チャン，
ビー リン チャン，
メイ フエイ ジャン，
メイ フエイ ジャン，
Original Assignee
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド, シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド filed Critical シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド
Publication of JP2016504040A publication Critical patent/JP2016504040A/ja
Publication of JP2016504040A5 publication Critical patent/JP2016504040A5/ja
Application granted granted Critical
Publication of JP6427502B2 publication Critical patent/JP6427502B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015551870A 2013-01-09 2014-01-09 アリールスルファターゼａの精製方法 Expired - Fee Related JP6427502B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750693P 2013-01-09 2013-01-09
US61/750,693 2013-01-09
PCT/US2014/010856 WO2014110246A1 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018122837A Division JP2018171067A (ja) 2013-01-09 2018-06-28 アリールスルファターゼａの精製方法

Publications (3)

Publication Number Publication Date
JP2016504040A JP2016504040A (ja) 2016-02-12
JP2016504040A5 JP2016504040A5 (enExample) 2017-02-16
JP6427502B2 true JP6427502B2 (ja) 2018-11-21

Family

ID=50002885

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015551870A Expired - Fee Related JP6427502B2 (ja) 2013-01-09 2014-01-09 アリールスルファターゼａの精製方法
JP2018122837A Withdrawn JP2018171067A (ja) 2013-01-09 2018-06-28 アリールスルファターゼａの精製方法
JP2019174155A Withdrawn JP2020015750A (ja) 2013-01-09 2019-09-25 アリールスルファターゼａの精製方法
JP2021183082A Active JP7407161B2 (ja) 2013-01-09 2021-11-10 アリールスルファターゼａの精製方法
JP2023173170A Active JP7663649B2 (ja) 2013-01-09 2023-10-04 アリールスルファターゼａの精製方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018122837A Withdrawn JP2018171067A (ja) 2013-01-09 2018-06-28 アリールスルファターゼａの精製方法
JP2019174155A Withdrawn JP2020015750A (ja) 2013-01-09 2019-09-25 アリールスルファターゼａの精製方法
JP2021183082A Active JP7407161B2 (ja) 2013-01-09 2021-11-10 アリールスルファターゼａの精製方法
JP2023173170A Active JP7663649B2 (ja) 2013-01-09 2023-10-04 アリールスルファターゼａの精製方法

Country Status (12)

Country Link
US (3) US11407984B2 (enExample)
EP (1) EP2943568B1 (enExample)
JP (5) JP6427502B2 (enExample)
CN (4) CN119979504A (enExample)
AU (3) AU2014205441B2 (enExample)
BR (1) BR112015015948B1 (enExample)
CA (1) CA2896979C (enExample)
EA (1) EA030551B1 (enExample)
ES (1) ES2768261T3 (enExample)
HK (1) HK1214622A1 (enExample)
MX (2) MX372711B (enExample)
WO (1) WO2014110246A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
CN108473558A (zh) * 2015-08-20 2018-08-31 豪夫迈·罗氏有限公司 Fkpa的纯化及其用于生产重组多肽的用途
CA3015685A1 (en) * 2016-03-16 2017-09-21 Phoenix Tissue Repair, Inc. Methods of purifying collagen 7
CN111065735B (zh) * 2017-08-31 2023-07-07 株式会社绿十字 用于纯化硫酸酯酶蛋白的方法
CA3086181A1 (en) * 2017-12-19 2019-06-27 Shire Human Genetic Therapies, Inc. Purified arylsulfatase a and compositons thereof
RU2020118032A (ru) * 2018-02-02 2022-03-02 Асераген, Инк. Способы лечения болезни фарбера
EP3774894A1 (en) 2018-04-12 2021-02-17 Amgen Inc. Methods for making stable protein compositions
CN112082832B (zh) * 2019-06-12 2022-03-29 华南理工大学 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110632052A (zh) * 2019-10-25 2019-12-31 山西师范大学 土壤芳基硫酸酯酶活性的荧光光谱检测法
EP4072600A1 (en) * 2019-12-12 2022-10-19 Eli Lilly and Company Methods for viral inactivation by environmentally compatible detergents
CN112759643B (zh) * 2021-03-17 2023-05-30 华兰生物工程股份有限公司 一种血清白蛋白的脱脂方法
CN116693659B (zh) * 2023-07-11 2025-03-28 浙江大学 一种分离重组人血白蛋白的两步混合模式层析方法
EP4778935A1 (en) * 2025-01-15 2026-07-22 Sartorius Stedim Biotech GmbH Method for purifying a target product

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
CA2041280A1 (en) * 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
ATE217799T1 (de) 1998-01-27 2002-06-15 Hemebiotech As Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
ID27417A (id) 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
AU774603B2 (en) 1999-07-27 2004-07-01 Zymenex A/S Production of rhPBGD and new therapeutic methods for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1409695A2 (en) 2000-11-15 2004-04-21 Genzyme Corporation Expression system for recombinant proteins
WO2002099092A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003002731A1 (en) 2001-06-29 2003-01-09 Hemebiotech A/S A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD)
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
NZ576986A (en) * 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
PL1740204T3 (pl) 2004-04-01 2018-08-31 Chiesi Farmaceutici S.P.A. Lecznicze zastosowanie alfa-mannozydazy
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
NO347673B1 (no) 2006-04-04 2024-02-19 Takeda Pharmaceuticals Co En sammensetning som omfatter konsentrert polypeptide og bruk derav.
CN105646643A (zh) * 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
JP6045493B2 (ja) * 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａのｃｎｓ送達の方法および組成物
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a

Also Published As

Publication number Publication date
EA201590826A1 (ru) 2015-11-30
JP2024001160A (ja) 2024-01-09
MX2020003798A (es) 2020-08-03
HK1216429A1 (en) 2016-11-11
WO2014110246A1 (en) 2014-07-17
CN119979504A (zh) 2025-05-13
ES2768261T3 (es) 2020-06-22
AU2022221475B2 (en) 2025-05-22
AU2014205441B2 (en) 2019-12-12
EA030551B1 (ru) 2018-08-31
CA2896979A1 (en) 2014-07-17
CN112126634A (zh) 2020-12-25
US11884945B2 (en) 2024-01-30
AU2020201079B2 (en) 2022-05-26
JP2016504040A (ja) 2016-02-12
BR112015015948A2 (enExample) 2017-08-15
US20240392268A1 (en) 2024-11-28
US11407984B2 (en) 2022-08-09
US20230235303A1 (en) 2023-07-27
JP2018171067A (ja) 2018-11-08
AU2020201079A1 (en) 2020-03-05
JP7663649B2 (ja) 2025-04-16
CN120665836A (zh) 2025-09-19
JP7407161B2 (ja) 2023-12-28
US12319940B2 (en) 2025-06-03
MX372711B (es) 2020-04-21
HK1214622A1 (zh) 2016-07-29
EP2943568B1 (en) 2019-11-20
JP2020015750A (ja) 2020-01-30
CN104903442A (zh) 2015-09-09
CA2896979C (en) 2023-05-02
US20150353904A1 (en) 2015-12-10
BR112015015948B1 (pt) 2022-05-17
AU2022221475A1 (en) 2022-09-22
AU2014205441A1 (en) 2015-06-25
MX2015008875A (es) 2015-10-22
EP2943568A1 (en) 2015-11-18
JP2022023225A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
JP7407161B2 (ja) アリールスルファターゼａの精製方法
JP6505629B2 (ja) 組換えイズロン酸２スルファターゼの精製
EP2729566B1 (en) Methods for purification of arylsulfatase a
HK1216429B (en) Methods for purification of arylsulfatase a
WO2024176112A1 (en) Large scale production of recombinant arylsulfatase a and compositions thereof
CN120189497A (zh) 纯化的芳基硫酸酯酶a及其组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181029

R150 Certificate of patent or registration of utility model

Ref document number: 6427502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees